People who have hot flashes, night sweats, sleep disruption, vaginal dryness, or other bothersome changes during perimenopause may benefit from hormone replacement therapy (HRT). HRT is most useful for symptoms caused by changing or falling estrogen levels, but it is not right for everyone. A clinician can help compare likely relief with personal risks, medical history, age, and how much symptoms affect daily life.
Who is most likely to benefit from HRT during perimenopause?
Perimenopause is the transition leading up to menopause, when hormone levels fluctuate and menstrual periods often become less predictable. Some people experience few changes, while others find that symptoms interfere with work, relationships, sleep, or everyday activities. HRT may be worth discussing when these changes are persistent, uncomfortable, or difficult to manage without treatment.
Symptoms that may prompt a conversation about HRT include:
- Hot flashes and night sweats: Sudden feelings of heat, sweating, and episodes that interrupt sleep.
- Sleep disruption: Difficulty staying asleep, especially when night sweats occur.
- Vaginal dryness or discomfort: Dryness, irritation, burning, or pain during sexual activity.
- Urinary symptoms: Increased urinary urgency, discomfort, or recurring urinary tract infections in some people.
- Other changes: Mood changes, difficulty concentrating, or reduced sexual desire that may occur around the menopausal transition.
The type of symptom matters when choosing treatment. The Mayo Clinic's guidance on perimenopause identifies systemic estrogen as the most effective treatment for hot flashes and night sweats. Vaginal estrogen may help relieve vaginal dryness, painful sex, and certain bladder symptoms. HRT may not address every symptom equally, so treatment should match the problems that matter most to the individual.
Which symptoms make HRT worth considering?
Hot flashes and night sweats that disrupt daily life
Systemic HRT, which allows estrogen to circulate throughout the body, is generally the most effective medical treatment for hot flashes and night sweats associated with menopause. These symptoms can occur during perimenopause, even while periods continue. For someone whose sleep, concentration, or daily routine is affected, HRT may offer meaningful relief when its expected benefits outweigh its risks.
Vaginal dryness and urinary discomfort
Some people have vaginal or urinary symptoms without troublesome hot flashes. In these cases, low-dose vaginal estrogen may be an appropriate option to discuss. It is available in forms such as vaginal creams, tablets, and rings and delivers estrogen mainly to vaginal tissues. Because it is intended for local symptoms, it is different from systemic HRT used for hot flashes and night sweats. Vaginal moisturizers and lubricants may also help, depending on the symptoms.
Symptoms that affect emotional well-being or concentration
Low mood, anxiety, irritability, poor sleep, and difficulty concentrating may occur during perimenopause. HRT may improve some symptoms, particularly when they are linked to hot flashes or night sweats, but it is not a universal treatment for depression, anxiety, or memory concerns. A healthcare professional can help assess whether hormonal changes may be contributing and whether another treatment, such as psychological therapy or a nonhormonal medicine, would be more suitable.
Does age affect who may benefit from HRT?
Age is an important part of the decision, but it is not the only factor. For otherwise suitable candidates, the balance of benefits and risks is often more favorable when systemic HRT is started before age 60 or within 10 years of menopause. This is a general guide, not a guarantee that treatment is safe for every person in that age group. The Mayo Clinic's review of hormone therapy benefits and risks emphasizes that age, medical history, treatment type, dose, and duration all influence the decision.
People who experience menopause earlier than usual may need a different discussion. Menopause before age 45, or primary ovarian insufficiency in which ovarian function declines before age 40, can mean a longer period of low estrogen. Hormone therapy may be considered for symptom relief and bone health, even when the treatment decision differs from that for someone entering menopause at the usual age. Assessment should take account of the cause of early menopause, overall health, and any reasons hormone therapy may be unsuitable.
Who may need to avoid HRT or have a more detailed assessment?
HRT is not suitable for everyone. Some medical conditions can make the risks of systemic hormone therapy outweigh its expected benefits. The Menopause Society's patient guidance on hormone therapy identifies several important situations in which hormone treatment is generally not recommended or requires careful specialist assessment.
- A history of breast cancer or cancer of the uterine lining.
- A previous blood clot, stroke, or significant cardiovascular disease.
- Liver disease.
- Unexplained vaginal or uterine bleeding.
These concerns need to be reviewed in context rather than assessed through a checklist alone. The type of HRT matters, and some people may have alternatives for specific symptoms. A history of cancer, clotting problems, or heart and blood vessel disease should be discussed with a clinician before considering systemic treatment. Unexplained bleeding should also be evaluated rather than assumed to be a routine part of perimenopause.
How does the type of HRT affect the decision?
HRT can be given as tablets, skin patches, gels, sprays, or vaginal products. Systemic preparations are used for symptoms such as hot flashes and night sweats, while low-dose vaginal estrogen is used mainly for local vaginal and urinary symptoms. The choice depends on symptom patterns, treatment preferences, medical history, and the balance of benefits and risks.
Whether someone still has a uterus is another important consideration. According to the American College of Obstetricians and Gynecologists (ACOG), systemic estrogen is generally prescribed with a progestogen for people who still have a uterus. The progestogen helps protect the uterine lining from the harmful effects of estrogen alone. People who have had a total hysterectomy may be able to use estrogen without a progestogen, depending on their circumstances.
The treatment plan should be individualized. A clinician can discuss the lowest effective dose, the most suitable preparation, possible side effects, and when to review progress. Breast tenderness, headaches, bloating, or spotting may occur. Follow-up allows the dose or formulation to be adjusted if symptoms remain troublesome or side effects develop.
What benefits and risks should be weighed before starting HRT?
The potential benefits include relief from hot flashes and night sweats, improvement in vaginal symptoms, and protection against bone loss in appropriate circumstances. The risks depend on factors such as the type of hormones used, the route of administration, dose, duration, age, and medical history. Systemic therapy may increase the risk of conditions such as blood clots, stroke, breast cancer, or gallbladder disease in some people. These risks should be weighed against the symptoms being treated and the expected benefit.
HRT should not be started solely to prevent heart disease. It is also not a general treatment for aging or a substitute for assessment of other health conditions. People who cannot take HRT, prefer not to use it, or have symptoms that do not respond adequately may have nonhormonal medicines, cognitive behavioural therapy, vaginal moisturizers, or other symptom-specific options to consider.
What should you discuss with a healthcare professional?
A useful appointment begins with the symptoms that affect you most and how they change over time. A healthcare professional will usually consider your age, menstrual history, symptom patterns, personal and family medical history, current medicines, and treatment preferences. Because hormone levels can fluctuate considerably during perimenopause, a single hormone blood test often cannot establish the stage of the transition on its own.
It can help to record changes in your periods, when symptoms occur, how they affect sleep or daily activities, and any treatments you have already tried. Seek medical assessment for symptoms that are worsening, difficult to interpret, or disruptive to daily life. Heavy or increasingly heavy bleeding also needs review, and any vaginal bleeding after 12 months without a period should be checked.
HRT does not provide contraception. Pregnancy may still occur during perimenopause, so contraception should be discussed separately if pregnancy is possible and not desired. The NHS guidance on estrogen HRT and contraception confirms that estrogen HRT is not a contraceptive method.
The decision to use HRT is personal and should reflect both symptom burden and health risks. For people whose perimenopausal symptoms interfere with quality of life, a discussion with a qualified healthcare professional can help clarify whether HRT, a local treatment, or a nonhormonal option is the most appropriate choice.